Q-omics provides the consensus-scored ZBTB38 profile across patient tissues and cancer cell-line models. ZBTB38 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZBTB38 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, ZBTB38 RNA expression shows 19,940 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where ZBTB38 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB38 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB38 survival associations across molecular data types. ZBTB38 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB38 RNA expression–survival associations across cancer types. High ZBTB38 expression shows unfavorable associations in DLBC, MESO, PAAD and LUAD, but favorable associations in KIRC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify KIRC as the clearest survival context for ZBTB38 RNA expression.
This table summarizes ZBTB38 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZBTB38. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB38 shows lower tumor expression in THCA, UCEC and BRCA and higher tumor expression in HNSC, LIHC and CHOL. The HNSC box plot shows higher ZBTB38 RNA expression in tumor versus normal tissue (log2 FC = +1.005, t-test p < 0.001).
This table shows molecular features associated with ZBTB38 in patient tissues and cancer cell lines. In patient samples, ZBTB38 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBTB38 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and UPPER_AERODIGESTIVE_TRACT.
